Vaine Michael, Lu Shan, Wang Shixia
Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
BioDrugs. 2009;23(3):137-53. doi: 10.2165/00063030-200923030-00001.
Infection with HIV type 1 (HIV-1), the causative agent of AIDS, is one of the most catastrophic pandemics to affect human healthcare in the latter 20th century. The best hope of controlling this pandemic is the development of a successful prophylactic vaccine. However, to date, this goal has proven to be exceptionally elusive. The recent failure of an experimental vaccine in a phase IIb study, named the STEP trial, intended solely to elicit cell-mediated immune responses against HIV-1, has highlighted the need for a balanced immune response consisting of not only cellular immunity but also a broad and potent humoral antibody response that can prevent infection with HIV-1. This article reviews the efforts made up to this point to elicit such antibody responses, especially with regard to the use of a DNA prime-protein boost regimen, which has been proven to be a highly effective platform for the induction of neutralizing antibodies in both animal and early-phase human studies.
1型人类免疫缺陷病毒（HIV-1）是艾滋病的病原体，是20世纪后期影响人类医疗保健最具灾难性的大流行病之一。控制这一大流行病的最大希望是研制出成功的预防性疫苗。然而，迄今为止，这一目标已被证明极难实现。最近一项名为STEP试验的IIb期实验性疫苗研究失败，该研究仅旨在引发针对HIV-1的细胞介导免疫反应，这凸显了需要一种平衡的免疫反应，不仅包括细胞免疫，还包括广泛而有效的体液抗体反应，以预防HIV-1感染。本文回顾了到目前为止为引发此类抗体反应所做的努力，特别是关于DNA初免-蛋白质加强方案的使用，该方案在动物和早期人体研究中已被证明是诱导中和抗体的高效平台。
